<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70312">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01663441</url>
  </required_header>
  <id_info>
    <org_study_id>NL201-Ⅲ-2012</org_study_id>
    <nct_id>NCT01663441</nct_id>
  </id_info>
  <brief_title>A Phase Ⅲ Study of Genetically Modified Recombinant Human Interleukin-11</brief_title>
  <acronym>mIL-11-Ⅲ</acronym>
  <official_title>Multicenter, Randomized Phase Ⅲ Study of Genetically Modified Recombinant Human Interleukin-11 to Prevent Chemotherapy-induced Thrombocytopenia in Cancer Patients Receiving Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Northland Biotech. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of  Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Northland Biotech. Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of genetically modified
      recombinant human IL- 11 (mIL-11), using original IL-11 as an active control, in a
      multicenter randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators recently developed a mutant form of rhIL-11 with improved stability. In in
      vitro experimental systems, mIL-11 was shown to endure chemical and proteolytic stresses
      more effectively, while retaining the biological activity of the original rhIL-11. The
      improved stability of mIL-11 was also demonstrated in the comparative pharmacokinetic study
      of subcutaneously delivered mIL-11 and rhIL-11 in the rodent and primate models. Based on
      its improved pharmacokinetic and pharmacodynamic features. In Phase II study shows that
      mIL-11 is well tolerated and has thrombopoietic activity equivalent to one third of the
      clinical dose of rhIL-11, indicating the potential of mIL- 11 for use in the treatment of
      CIT. This study is a phase III, single-blinded, randomized,multicenter,cross-over study
      designed to evaluate efficacy and safety of low-dose mIL-11 on CIT patients receiving
      suitable chemotherapeutic regimen for treating cancer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Comparison of average platelet counts between mIL-11 and rhIL-11 at day 21 after the initiation of chemotherapy</measure>
    <time_frame>day 21 after the initiation of chemotherapy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery time of platelet counts from nadir to normal level</measure>
    <time_frame>21days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of average nadir platelet counts between mIL-11 and rhIL-11 during chemotherapy cycles</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Chemotherapy-induced Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>IL-11</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mIL11:   7.5 μg/kg rhIL-11: 25μg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mIL-11</intervention_name>
    <description>mIL-11:7.5μg/kg ，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy； rhIL-11:25μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；</description>
    <arm_group_label>IL-11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological verification of malignancy at the time of initial diagnosis；

          -  Patients (age,18-75 years) receiving chemotherapy, who had experienced platelet
             counts below 75×109/L；

          -  patients were required to have adequate bone marrow,hepatic, and renal     functions
             at the time of study entry；

          -  ECOG  ≤2；

          -  patients to have normal laboratory findings:while white blood count
             &gt;3.0×109/L,platelet count ≥100×109/L, and AST and/or ALT lesser than 2.5 times the
             upper limit of the normal value；

          -  The estimated life expectancy of the patient was more than 3 months.

        Exclusion Criteria:；

          -  patients who received total body irradiation；

          -  patients with childbearing potential；

          -  patients who were breast-feeding or pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Northland Biotech. Co., Ltd.</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100085</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanshan Ma, Master</last_name>
      <phone>86-10-82890893</phone>
      <phone_ext>19</phone_ext>
      <email>mashanshan@northland-bio.com</email>
    </contact>
    <investigator>
      <last_name>Shikai Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>August 10, 2012</lastchanged_date>
  <firstreceived_date>August 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Interleukin-11</keyword>
  <keyword>Platelet</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oprelvekin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
